Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

julio1enrique 3319 posts  |  Last Activity: May 24, 2013 3:59 PM Member since: Jan 22, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • julio1enrique by julio1enrique May 24, 2013 3:59 PM Flag

    No LNG plant for IOC.
    The PM won... (Exxon....).
    Now we now why Phil took off.....

    My love was killed.
    POLITICS !!!!!!!!!!!!!!!

  • Reply to

    Exxon... Exxon... Exxon...

    by julio1enrique May 24, 2013 10:14 AM
    julio1enrique julio1enrique May 24, 2013 12:11 PM Flag

    Hhhhmmmm.... nobody read that the PM decided to have only one LNG plant for the moment?

  • julio1enrique by julio1enrique May 24, 2013 10:14 AM Flag

    A lot of members were ungry with me some years ago when I said: Exxon.... Exxon.... Exxon...

    Well, now a PR said: Exxon !!!! Then, congratulations Julio.

    The answer is in POLITICS. Phil was out? Why? Today we have the answer. PNG... PM... Duma... politics.... politics....

    But I don't like the agreement. All you know I was an IOC fun, number one !!!! But this agreement is only POLITICS and very bad for IOC. Nothing for IOC... no LNG plant.... only money to drill in the medium term.

    I was out today at $ 102 in my small position and we'll see red today... I think so...

    Julio

  • julio1enrique by julio1enrique Mar 21, 2013 2:39 PM Flag

    Hopes... rumors... facts....

    Jo jo jo

  • Jo jo jo.....
    Some years ago I mentioned the name of a big oil player.
    Now, believe or not....

    Jo jo jo

    Good luck !!!!!!!!!!!!!!!

    Sentiment: Strong Buy

  • Reply to

    Raymond James terminating coverage of IOC

    by jonathanswesche Dec 20, 2012 2:28 PM
    julio1enrique julio1enrique Dec 20, 2012 2:46 PM Flag

    Yes, I can confirm that. Pavel thinks -now- IOC is a fraud.
    Please, sell your 100 shares fastly. I'll buy them.

    Sentiment: Strong Buy

  • See Roche web site.

    Investor Update
    Basel, 20 December 2012
    Roche’s vismodegib named Drug Discovery of the Year by the British Pharmacological Society
    Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the first in class Hedgehog pathway inhibitor vismodegib, was named Drug Discovery of the Year by the British Pharmacological Society. The award, which celebrates the importance of pharmacology in the development of new medicines, was presented to the vismodegib team because of the detailed pharmacokinetic/pharmacodynamic analysis that was completed during the drug development process. Vismodegib is currently approved in the US and Mexico for the treatment of adults with an advanced form of the common skin cancer basal cell carcinoma.
    Vismodegib works by selectively targeting and blocking abnormal signals in a pathway involved in regulating growth and development in the early stages of life (the Hedgehog signalling pathway). As a person matures, the Hedgehog signalling pathway normally becomes less active, working only to maintain or repair tissue. However in some people malfunctions or abnormal activation occurs; such abnormal activation has been shown to play an important role in the development of certain types of cancer.
    Rick Graham, Clinical Pharmacologist and acting Global Development Leader for vismodegib at Genentech, commented, “We are very proud that our understanding of the Hedgehog signalling pathway enabled us to develop a medicine which today is providing meaningful benefit to patients with advanced basal cell carcinoma.”
    Nearly all (90 percent) advanced basal cell carcinoma lesions demonstrate abnormal activation of the Hedgehog signalling pathway, and in both a clinical and real world setting, treatment with vismodegib has been shown to provide significant clinical benefit and to set a new standard of care for patients with this potentially disfiguring and debilitating disease.
    The British Pharmacological Society’s Drug Discovery of the Year award celebrates the importance of pharmacology in the development of new medicines. The winning team was selected by a judging panel of experts in industrial pharmacology, following nominations made to BPS by its members worldwide.
    About vismodegib
    Vismodegib is an investigational medicine designed to selectively target abnormal signalling in a cell growth pathway, known as the Hedgehog signalling pathway which is implicated in the development of certain types of cancer, including basal cell carcinoma.
    Basal cell carcinoma is the most common type of skin cancer in Europe, Australia and the United States. In advanced basal cell carcinoma, if the disease is left untreated or recurs in the same location after surgery or radiotherapy, it may advance further into surrounding areas such as sensory organs (ears, nose and eyes), bone, or other tissues. Depending on the location of the lesion, some cases of advanced basal cell carcinoma can be disfiguring, and treatment with surgery or radiation can lead to the loss of sensory organs and their functions such as eyesight or hearing.
    In January 2012 vismodegib became the first licensed medicine for patients with advanced forms of basal cell carcinoma when it was approved by the U.S. FDA under the brand name Erivedge™. It has since been approved by the Federal Commission for Protection Against Health Risks in Mexico.
    Roche has submitted a marketing approval application for vismodegib to the European Medicines Agency and is working closely with regulatory authorities in other countries to make the medicine available to patients with advanced basal cell carcinoma as quickly as possible.
    Roche is developing vismodegib under a collaboration agreement with Curis, Inc. Vismodegib was discovered by Genentech and jointly validated by Genentech and Curis through a series of preclinical studies. Through this collaboration, Genentech (U.S.), Roche (ex-U.S. excluding Japan) and Chugai Pharmaceuticals (Japan) are responsible for the clinical development and commercialisation of vismodegib. Curis is eligible to receive cash payments upon the successful achievement of specified clinical development and regulatory approval milestones, as well as royalties upon commercialisation of vismodegib.

    Sentiment: Strong Buy

  • The shorts increased their bets:

    11/30/2012 10,646,417
    11/15/2012 10,091,771
    10/31/2012 9,461,886
    10/15/2012 9,189,753

    Sentiment: Strong Buy

  • JO JO JO JO JO JO

    A rich country.... PNGOIL.....PNGOIL...... PNGOIL....

  • julio1enrique by julio1enrique Nov 29, 2012 1:41 PM Flag

    Wait until tomorrow !!!!!!!!!!!!!!!

    Too late.

    Sentiment: Strong Buy

  • MUMMMMMMMMMMMMMMMMMMMMM !!!!!!!!!!
    Oil in Antelope 3 Mum !!!!!!!!!!
    Tonky Tonky

    Jo jo jo jo

    Sentiment: Strong Buy

  • Jo jo jo jo

    Pet will watch some pictures again....

    Jo jo jo jo

    COOOOOOOOVVVVVVVERRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRRR

    Sentiment: Strong Buy

  • julio1enrique by julio1enrique Nov 29, 2012 9:42 AM Flag

    Based on current cost assumptions and assuming the full work program is completed, the initial cash payments and work program consideration are estimated to represent a combined total value of US$345 million, plus a final resource payment as outlined below.

    The final resource payment is intended to be determined after completion of the planned Triceratops-8 appraisal well, and calculated on volumes based on the total amount of Certified Resources within the Triceratops structure comprised of gas classified as 1P or 1C, at US$3.85/mmbtu, and 2P or 2C at US$2.85/mmbtu, and condensate or oil classified as 1P or 1C, at US$36/boe and 2P or 2C at US$30/boe; less adjustments related to the initial cash payments and the carried costs. The final resource payment will be paid out over time, similar to a royalty payment structure, with InterOil and other upstream interest holders receiving 70% of all cash flows from PRE’s participating interest in commercial sales proceeds until the entire final resource payment is paid in full.

    Sentiment: Strong Buy

  • Reply to

    Dec 19 2011 - Feb 8 2012

    by julio1enrique Nov 28, 2012 9:29 PM
    julio1enrique julio1enrique Nov 28, 2012 9:46 PM Flag

    Eric, I am not Ken. I am Julio and I live in Tokyo until June 2013.
    Good nite for you.

    Sentiment: Strong Buy

  • julio1enrique by julio1enrique Nov 28, 2012 9:29 PM Flag

    Out of office all the day. Nice day... I'll enjoy the chart.

    Dec 19 2011 $ 44.48
    Feb 8 2012 $ 74.73
    50 days 68%

    Only a remember.

    Sentiment: Strong Buy

  • julio1enrique by julio1enrique Nov 27, 2012 3:50 PM Flag

    57.80.
    Nice entry point for more shares.

    A TRIPLE in six weeks. Only IOC can do that.

    Jo jo jo jo jo jo

    Sentiment: Strong Buy

  • julio1enrique by julio1enrique Nov 27, 2012 3:19 PM Flag

    Woodside choice.

    Coooovvverrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr !!!!

    Sentiment: Strong Buy

  • Reply to

    WOODSIDE WOODSIDE WOODSIDE

    by julio1enrique Nov 27, 2012 8:09 AM
    julio1enrique julio1enrique Nov 27, 2012 3:17 PM Flag

    Jo jo jo jo

    Coverrrrrrrrrrrrrrrrrrrrrrrrrrrrrr !!!!!!!!!1

    Sentiment: Strong Buy

  • Reply to

    MESSAGE TO TOKAN

    by julio1enrique Nov 27, 2012 9:50 AM
    julio1enrique julio1enrique Nov 27, 2012 11:40 AM Flag

    Pssss.... say to your boss: "COVER". He could buy a few hundreds shares....

    Sentiment: Strong Buy

  • Reply to

    Wall Street Journal today on IOC

    by julio1enrique Nov 27, 2012 9:53 AM
    julio1enrique julio1enrique Nov 27, 2012 11:34 AM Flag

    Look for the news and read. It is free. WSJ

    Sentiment: Strong Buy

CRIS
3.18-0.10(-3.05%)Jul 2 4:00 PMEDT